India Pharma Outlook Team | Thursday, 17 September 2026
Pharma faces a clear pipeline paradox today. Companies chase AI tools to accelerate R&D while intellectual property cracks widen and quality gaps surface.
Big players pour resources into artificial intelligence partnerships that promise faster discovery. At the same time, trial failures, biosimilar lawsuits, and recurring recalls expose soft spots in pipelines and manufacturing.
These tensions define the current moment. Investors watch closely as firms balance innovation bets against courtroom fights and FDA scrutiny.
These updates capture the push-pull perfectly: bold AI moves, stalled programs, patent battles, and quality questions that refuse to fade.
Novartis halted development of its experimental ALS drug VHB937, also known as lifonebart, after the mid-stage trial missed both primary and secondary goals. The study enrolled 251 patients with early-stage ALS within two years of symptom onset.
The drug targets TREM2 to regulate immune responses and waste clearance in the brain. This marks another setback for the Swiss company this year after a heart drug disappointment, a muscle-wasting drug failure, and the halt of most rap-cel cell therapy studies following patient deaths.
Novartis continues to study the same molecule in Alzheimer’s disease. Pipeline pressure keeps rising as investors demand clearer progress.
Also Read: How Can India Pharma Bridge the Gap Between Innovation and Access
Novo Nordisk partnered with Anthropic to deploy Claude models and Claude Science across its research and development workflows. The Danish company will test the tools on scientific problems where joint capabilities deliver the biggest impact.
CEO Mike Doustdar noted that AI tools open entirely new scientific opportunities and aid understanding of human biology and drug mechanics. Anthropic CEO Dario Amodei highlighted the potential to shorten research timelines and improve outcomes. This move fits the broader industry race to use frontier AI models for faster discovery and software development.
Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court to block its proposed Opdivo (nivolumab) biosimilar. The lawsuit alleges infringement of seven U.S. patents. Opdivo generated more than USD 5.9 billion in U.S. revenue last year. Amgen has applied for FDA approval and remains confident it will join the first wave of Opdivo biosimilars. BMS expects patent exclusivity until 2028.
Patent infringement lawsuits in the U.S. District Court for the District of Delaware typically run anywhere from 18 to 30 months to reach a trial or final resolution, barring an early settlement. A long Delaware fight could delay market entry and reshape competitive planning for years.
Ajanta Pharma USA initiated a voluntary Class III recall of 403,200 tablets of Fluphenazine Hydrochloride 1 mg after an out-of-specification impurity result. During 18-month long-term stability testing via HPLC, Impurity-A hit 1.1 percent.
Class III means the product violates manufacturing or quality standards but is unlikely to cause adverse health consequences. This is not Ajanta’s first 2026 recall. Earlier this year, the firm faced a Class II product mix-up with Aripiprazole tablets and nitrosamine impurity issues in Duloxetine. The pattern raises sharper questions about recurring quality failures and what they signal for Indian-manufactured generics in the U.S. market.
India supplies roughly 40 percent of the generic drugs consumed in the U.S. Recurrent failures therefore send mixed reputational signals. These episodes together paint a clear picture. Pharma races toward AI-powered R&D while IP battles and quality cracks demand equal attention. The companies that close those gaps fastest will shape the next chapter of the pipeline.
